Recently, Zhao et al. have demonstrated that conjugation of targeted peptides of mannose receptor, namely CSPGAK (CD206s, 561.7 Da) and CSPGAKVRC (CD206, 920.1 Da) (CD206 and CD206s), to CPMV functions as a promising avenue for cancer immunotherapy directed at M2 macrophages [357]. This evidence concerns the gene MRC1 and cancer.